<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="200">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01410370</url>
  </required_header>
  <id_info>
    <org_study_id>Endu-201107</org_study_id>
    <nct_id>NCT01410370</nct_id>
  </id_info>
  <brief_title>Continuous Endostar Infusion Combined With Radiotherapy in Patients With Brain Metastases</brief_title>
  <official_title>Phase II Study of Continuous Endostar Infusion Combined With Radiotherapy for the Treatment of Patients With Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Simcere Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First People's Hospital of Lianyungang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu Simcere Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <authority>China:SFDA</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the clinical efficacy and safety of continuous Endostar
      infusion combined with radiotherapy for treatment of brain metastases.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>1 month after initial treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum VEGF Levels</measure>
    <time_frame>at baseline and 1 month after initial treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VEGF levels in tumor tissue</measure>
    <time_frame>at baseline and 1 month after initial treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>up to 1 month after last dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Edema</measure>
    <time_frame>1 month after initial treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy plus Endostar</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>6MV-X ray</intervention_name>
    <description>3Gy/time, 5 times/week, a total of 10 times</description>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endostar</intervention_name>
    <description>7.5mg/m2/d, continuous infusion, in parallel with radiotherapy</description>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed malignancy with presence of intraparenchymal brain
             metastases

          -  Karnofsky performance status ≥ 40

          -  Measurable disease according to RECIST criteria

          -  Hematologic function: WBC ≥ 4.0×109/L, PLT ≥ 80×109/L, Hb ≥ 90g/L

          -  Renal function: Cr ≤ 2.0×ULN

          -  Hepatic function: BIL ≤ 2.0×ULN, ALT/AST ≤ 5.0×ULN

          -  Adequate cardiac function

          -  Life expectancy ≥ 3 months

        Exclusion Criteria:

          -  Evidence of bleeding diathesis or serious infection

          -  Serious cardiovascular disease (congestive heart failure, uncontrollable arrhythmia,
             unstable angina, myocardial infarction, serious heart valve disease, resistant
             hypertension)

          -  Uncontrollable mental and nervous disorders

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaodong Jiang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First People's Hospital of Lianyungang</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaodong Jiang, MD</last_name>
    <phone>86-0518-85605120</phone>
  </overall_contact>
  <location>
    <facility>
      <name>The First People's Hospital of Lianyungang</name>
      <address>
        <city>Lianyungang</city>
        <state>Jiangsu</state>
        <zip>222002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaodong Jiang, MD</last_name>
      <phone>0518-85605120</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 22, 2013</lastchanged_date>
  <firstreceived_date>July 20, 2011</firstreceived_date>
  <responsible_party>
    <name_title>Xiaodong Jiang</name_title>
    <organization>The First People's Hospital of Lianyungang</organization>
  </responsible_party>
  <keyword>Endostar</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Brain Metastases</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
